|
August 19, 2021
|
Progenity Announces Proposed Underwritten Public Offering of Common Stock and Warrants
|
|
August 12, 2021
|
Progenity Provides Corporate Update and Reports Second Quarter 2021 Financial Results
|
|
August 5, 2021
|
Progenity to Report Second Quarter 2021 Financial Results and Provide Corporate Update
|
|
July 29, 2021
|
Progenity Announces Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out Test
|
|
June 30, 2021
|
Progenity Announces Appointment of Surbhi Sarna to its Board of Directors
|
|
June 17, 2021
|
Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board
|
|
June 15, 2021
|
Progenity to Participate in the Raymond James 2021 Human Health Innovation Conference
|
|
June 10, 2021
|
Progenity Announces $40 Million Private Placement
|
|
June 2, 2021
|
Progenity Launches Strategic Transformation into Biotech Company, Eliminating Costs of Progenity Genetics Lab and Focusing on Robust, Innovative R&D Pipeline
|
|
May 26, 2021
|
Progenity Provides Results from Key Study for Its Targeted Therapeutics Program
|